Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
New Westminster, British Columbia, Canada
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Research Site
-
-
Ontario
-
Ajax, Ontario, Canada
- Research Site
-
Cambridge, Ontario, Canada
- Research Site
-
Windsor, Ontario, Canada
- Research Site
-
-
-
-
-
Chihuahua, Mexico
- Research Site
-
Mexico City, Mexico
- Research Site
-
-
Distrito Federal
-
Mexico City, Distrito Federal, Mexico
- Research Site
-
-
Guanajuato
-
Celaya, Guanajuato, Mexico
- Research Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico
- Research Site
-
-
-
-
-
Baia Mare, Romania
- Research Site
-
Brasov, Romania
- Research Site
-
Bucuresti, Romania
- Research Site
-
Dolj, Romania
- Research Site
-
Iasi, Romania
- Research Site
-
Suceava, Romania
- Research Site
-
-
-
-
-
Johannesburg, South Africa
- Research Site
-
Pretoria, South Africa
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- Research Site
-
-
California
-
Concord, California, United States
- Research Site
-
Fresno, California, United States
- Research Site
-
-
Colorado
-
Denver, Colorado, United States
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States
- Research Site
-
-
Ohio
-
Mogadore, Ohio, United States
- Research Site
-
-
Oregon
-
Corvallis, Oregon, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with type 2 diabetes
- If treated with a thiazolidinedione (TZD) alone, the TZD dose must have been stable for at least 120 days
- The dose of TZD must be: Rosiglitazone (≥4 mg/day) or pioglitazone (≥30 mg/day)
- The metformin dose has been stable for at least 90 days
- Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 10.0%, inclusive.
- Have a body mass index (BMI): 25 kg/m2 < BMI < 45 kg/m2.
Exclusion Criteria:
- Have participated in this study previously or any other study using exenatide (AC2993/LY2148568) or glucagon-like peptide-1 (GLP-1) analogs, or have been previously treated with exenatide or GLP-1 analogs
- Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
- Have been treated with exogenous insulin for more than 1 week within the 2 months prior to screening
- Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or similar over-the-counter medications) within 3 months prior to screening.
Are currently treated with any of the following excluded medications:
- Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within 3 months prior to screening
- Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within 3 months of screening
- Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin) within 3 months prior to screening
- Pramlintide acetate injection within 3 months prior to screening
- Drugs that directly affect gastrointestinal motility, including, but not limited to: Metoclopramide, cisapride, and chronic macrolide antibiotics
- Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding study start
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
|
|
Experimental: Exenatide twice daily (BID)
|
subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Glycosylated Hemoglobin (HbA1c)
Time Frame: baseline and 26 weeks
|
Change in HbA1c from baseline to endpoint after 26 weeks of treatment (i.e., HbA1c at endpoint minus HbA1c at baseline)
|
baseline and 26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Patients Achieving HbA1c <= 7%
Time Frame: 26 weeks
|
Percentage of intent-to-treat (ITT) patients who had HbA1c > 7% at baseline that decreased to <= 7% at endpoint (Week 26 or early discontinuation)
|
26 weeks
|
|
Percentage of Patients Achieving HbA1c <= 6.5%
Time Frame: 26 weeks
|
Percentage of ITT patients who had achieved HbA1c <= 6.5% at endpoint (Week 26 or early discontinuation)
|
26 weeks
|
|
Change in Fasting Serum Glucose (FSG)
Time Frame: baseline and 26 weeks
|
Change in FSG from baseline to endpoint (26 weeks)
|
baseline and 26 weeks
|
|
Change in Body Weight
Time Frame: baseline and 26 weeks
|
Change in body weight from baseline to endpoint (26 weeks)
|
baseline and 26 weeks
|
|
Change in Waist Circumference
Time Frame: baseline and 26 weeks
|
Change in waist circumference from baseline to endpoint (26 weeks)
|
baseline and 26 weeks
|
|
Change in Beta-cell Function
Time Frame: baseline and 26 weeks
|
Change in homeostatic model assessment-beta cell (HOMA-B) from baseline to endpoint (Week 26) (outcome measure is presented as the ratio of endpoint HOMA-B divided by baseline HOMA-B).
HOMA-B is a measure of pancreatic beta-cell function.
|
baseline and 26 weeks
|
|
Change in Insulin Sensitivity.
Time Frame: baseline and 26 weeks
|
Change in homeostatic model assessment-insulin sensitivity (HOMA-S) from baseline to endpoint (26 weeks) (outcome measure is presented as the ratio of endpoint HOMA-S divided by baseline HOMA-S).
|
baseline and 26 weeks
|
|
Number of Subjects Who Experienced an Episode of Minor Hypoglycemia
Time Frame: 26 weeks
|
Overall number of subjects who experienced an episode of minor hypoglycemia.
|
26 weeks
|
|
Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score
Time Frame: baseline and 26 weeks
|
IWQOL-Lite analysis of change from baseline to endpoint (26 weeks).
IWQOL-Lite is a 31-item questionnaire, assessing the domains of physical function, self-esteem, sexual life, public distress, and work.
Response categories for each item range from 1 = "never true" to 5 = "always true."
|
baseline and 26 weeks
|
|
Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score
Time Frame: baseline and 26 weeks
|
EQ-5D Score - change from baseline to endpoint (26 weeks).
EQ-5D is a 5-item questionnaire used to characterize current health states.
The tool and accompanying visual analog scale (VAS) assess 5 domains of quality of life, including mobility, self-care, usual activity, pain, and anxiety/depression.
Weights are used to score the responses to the 5 domains, with 3 options possible in each domain: extreme problems, some/moderate problems, or no problems.
Scores range from 0 to 1, with a score of 1 representing a perfect health state.
|
baseline and 26 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010 Dec;12(12):1058-65. doi: 10.1111/j.1463-1326.2010.01251.x.
- Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012 Jul;124(4):21-32. doi: 10.3810/pgm.2012.07.2567.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H8O-MC-GWCG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.